Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
SPARC shares hit a fresh 52-week high after rising 17% in the past week. The rally follows a series of positive developments, including a $195 million PRV sale, a ₹600 crore promoter fund infusion, and a return to profitability in FY26.
Sun Pharma Advanced Research Company's share price was trading at ₹278.65 as of 12:25 PM on July 8, 2026, up 106.36% YTD and around 17% over the past one week. The stock touched an intraday high of ₹289.00, marking a fresh 52-week high, and a low of ₹262.40 during the session.
Trading volume stood at 34.90 lakh shares compared with the 30-day average of 50.50 lakh shares. The sharp rally follows a series of key developments, including an FDA voucher award, a high-value asset sale, a promoter fund infusion, and a financial turnaround in the first half of calendar year 2026.
The chain of events began on February 3, 2026, when SPARC received a Rare Paediatric Disease Priority Review Voucher from the United States Food and Drug Administration. The voucher was awarded in connection with the FDA's approval of Sezaby, a benzyl alcohol- and propylene glycol-free injectable formulation of phenobarbital sodium for the treatment of neonatal seizures.
A PRV is a transferable certificate that allows any pharmaceutical company to request expedited review of a future drug application, cutting the standard FDA review timeline by approximately four months. In an industry where speed to market carries significant commercial value, PRVs frequently change hands at substantial premiums.
Just less than three months after obtaining the voucher, SPARC made the following announcement: on April 30, 2026, the company entered into a definitive asset purchase agreement for the sale of the PRV to an unnamed third party for $195 million. This transaction was conditional on satisfaction of customary closing conditions, which included expiration of the relevant waiting period under US antitrust law. Anil Raghavan, SPARC’s CEO, revealed that the company will use the funds to advance the development of pipeline assets and its external innovation strategy.
Another significant development occurred on May 19, 2026, when SPARC's Securities Allotment Committee made an allotment of 3,85,10,000 convertibles to Shanghvi Finance Private Limited, a promoter group company, at an issue price of ₹155.80 per warrant. The issuance was made on a preferential basis, following approvals from the Board of Directors in January 2026 and the Extraordinary General Meeting in February 2026. The total price at an issue of ₹155.80 per warrant works out to be around ₹600 crore.
As per SEBI's ICDR Regulations, 25% of the warrant issue price is payable upfront, and the company received ₹149.99 crore at the time of allotment. Each warrant is convertible into one fully paid-up equity share of face value ₹1 each. The equity share capital does not change on allotment of warrants; it will be enhanced only upon conversion.
SPARC's consolidated financial results for the year ended March 31, 2026, show the cumulative financial impact of the PRV sale. Total revenue from operations came in at ₹1,879 crore for FY26, compared with ₹72 crore in FY25. Of this, ₹1,840 crore was classified as other operating revenue, representing the PRV sale proceeds. Revenue from contracts with customers, the company's underlying clinical and licensing activity, stood at ₹39 crore in FY26, down from ₹72 crore in FY25, indicating a decline in core recurring income even as total revenue expanded sharply.
Profit before tax came in at ₹1,553 crore against a loss before tax of ₹343 crore in FY25. Net profit for FY26 stood at ₹1,553 crore, reversing the net loss of ₹343 crore reported in FY25.
The PRV proceeds were recognised entirely in the quarter ended March 31, 2026. Q4 FY26 revenue from operations stood at ₹1,853 crore, driven almost entirely by the ₹1,840 crore PRV income. Revenue from contracts with customers for the quarter was ₹13 crore and Net profit for the quarter came in at ₹1,761 crore. By comparison, Q4 FY25 reported a net loss of ₹60 crore on total revenue of ₹27 crore, and Q3 FY26 reported a net loss of ₹80 crore.
Beyond the one-time PRV income, SPARC's pipeline continues in clinical development. Vodobatinib (SCO-088), a BCR-ABL inhibitor for refractory chronic myelogenous leukaemia, and Vibozilimod (SCD-044), an S1PR1 agonist for psoriasis and atopic dermatitis, are both in Phase 2 trials. Earlier-stage candidates include SCD-153 for alopecia areata and SBO-154, an anti-MUC-1 antibody-drug conjugate for multiple tumour types. The company has indicated that PRV proceeds will be directed towards advancing these assets and pursuing external innovation opportunities.
FY26 performance of SPARC shows a definite financial turnaround since SPARC recorded a consolidated net profit of ₹1,553 crore after posting a net loss of ₹343 crore in FY25. This was mainly due to the one-time transaction of selling PRV for $195 million made during Q4 FY26. The additional financial buffer provided by the promoter warrant issuance for approximately ₹600 crore is also significant.
The 106.36% rise in the share price of SPARC YTD up to July 8, 2026, demonstrates how the market has responded cumulatively to these events. Looking ahead, the recurring revenue generation capability of SPARC through its clinical pipeline is going to be the focus of interest for the investors since the revenue generated through contracts remains low compared to one-off PRV income.
Source: Dalal Street Investment Journal (DSIJ), BSE, NSE
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading